RE:RE:RE:Shareholder value???Tencents wrote: In addition to above we should take into consideration aezs management comments in its financial statements which states aezs expects to make significant losses for the foreseeable future
this probably meabb nes the cash on hand will be eaten up by end 2025 and tax losses will not be used in the short to medium term
If the merger was cancelled the parties could have informed us by now. We've received nothing. A delay in the deal could bring new developments as AEZS's diagnostic clinical trial was to be fully enrolled by the end of 2023. Results from the trial could be near and this could support a licensing deal. CZO's avenanthramide clinical trial could also be nearing completion of the single ascending dose portion of the trial. There is also the question of CZO's main client returing and the launch of the powder formulations. The 5X PGX scale-up was also to be commissioned in Q1 as Natex works on the 10X scale-up. There could be an update here. CZO had als designed an animal trial for the immune booster as of the day the financials were released which could help increase confidence in that program.